# US 10,369,166 B2 · Pharmaceutical compositions for treating ebola virus disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,166 B2
- Document ID: US10369166B2
- Status: Granted
- Kind: B2
- Application number: 15/514,520
- Filed: 2015-09-20
- Published: 2017-08-17
- Granted: 2019-08-06
- Earliest claimed: 2014-09-30
- Applicants: Susan Eve Vecht-Lifshitz
- Inventors: Susan Eve Vecht-Lifshitz
- Web page: https://patentgrep.com/patent/US10369166B2

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/12: Ketones
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/365: Lactones
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/569: substituted in position 17 alpha, e.g. ethisterone
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 36/258: Panax (ginseng)
- A61K 38/06: Tripeptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds and pharmaceutical compositions adapted to reduce a load of an RNA virus by at least 50%, the virus causing a pathogenic disease in a mammalian subject, the compound adapted to inhibit the formation of S-adenosyl methionine (SAM) in the virus, the compound being a DOTIL inhibitor, wherein the compound has a molecular weight of less than 1000, and a therapeutic index (TI=LD.sub.50:ED.sub.50) greater than 30 in the mammalian subject.

## Claims

### Claim 1

A method for reducing a load of an infectious RNA virus causing a hemorrhagic pathogenic disease in a mammalian subject, the method comprising administering to said subject a DOT1L inhibitor compound, said compound adapted to reduce a load of said RNA virus by at least 50% in said mammalian subject, wherein said compound has a therapeutic index (TI=LD50:ED50) greater than 30 in said mammalian subject against said infectious RNA virus, wherein said infectious RNA virus is Ebola virus.

### Claim 2 (depends on 1)

A method according to claim 1, wherein said DOT1L inhibitor compound has an IC80 of less than 1 micromolar.

### Claim 3 (depends on 1)

A method according to claim 1, wherein said DOT1L inhibitor compound has an ED50 of less than 1 micromolar.

### Claim 4 (depends on 1)

A method according to claim 1, wherein said DOT1L inhibitor compound is formulated in a pharmaceutical composition.

### Claim 5 (depends on 4)

A method according to claim 4, wherein said DOT1L inhibitor compound is EPZ5676.

### Claim 6 (depends on 4)

A method according to claim 4, wherein the pharmaceutical composition is provided in a dosage form selected from an injectable dosage form, infusible dosage form, inhalable dosage form, edible dosage form, slow release dosage form, oral dosage form or combinations thereof.

### Claim 7 (depends on 1)

A method according to claim 1, wherein said mammalian subject is human.

### Claim 8 (depends on 1)

A method according to claim 1, wherein said load is reduced by 80% or more in said mammalian subject.

### Claim 9 (depends on 1)

A method according to claim 1, wherein said administering step is performed by oral, parenteral, transdermal, intra-venous or intra-muscular administration.